Stephanie Grabow

3.1k total citations · 1 hit paper
33 papers, 2.2k citations indexed

About

Stephanie Grabow is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Stephanie Grabow has authored 33 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 14 papers in Immunology and 12 papers in Oncology. Recurrent topics in Stephanie Grabow's work include Cell death mechanisms and regulation (21 papers), Cancer-related Molecular Pathways (9 papers) and Phagocytosis and Immune Regulation (5 papers). Stephanie Grabow is often cited by papers focused on Cell death mechanisms and regulation (21 papers), Cancer-related Molecular Pathways (9 papers) and Phagocytosis and Immune Regulation (5 papers). Stephanie Grabow collaborates with scholars based in Australia, United States and Sweden. Stephanie Grabow's co-authors include Andreas Strasser, Alex R. D. Delbridge, David L. Vaux, Philippe Bouillet, David C.S. Huang, Matthew S. Davids, Rebecca Valentin, W. Douglas Fairlie, Daniel H.D. Gray and Christoph Borner and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Stephanie Grabow

33 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

2016 582 citations Alex R. D. Delbridge, Stephanie Grabow et al. Nature reviews. Cancer profile →

Peers

Stephanie Grabow

IMMUN

ONCOL

EPIDE

Verena Labi Austria

Miriam Erlacher Germany

Dexing Fang United States

Leonie A. Cluse Australia

Meike Vogler Germany

Zhen Zhao United States

Tim Hon Man Chan United States

Anna Scuto United States

Rémy Castellano France

Alex R. D. Delbridge Australia

Verena Labi Austria

Stephanie Grabow

1.6k ×1.0

723 ×1.2

IMMUN

592 ×1.0

ONCOL

387 ×1.4

225 ×1.0

EPIDE

Citations per year, relative to Stephanie Grabow Stephanie Grabow (= 1×) peers Verena Labi

Countries citing papers authored by Stephanie Grabow

Since Specialization

Citations

This map shows the geographic impact of Stephanie Grabow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephanie Grabow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephanie Grabow more than expected).

Fields of papers citing papers by Stephanie Grabow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephanie Grabow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephanie Grabow. The network helps show where Stephanie Grabow may publish in the future.

Co-authorship network of co-authors of Stephanie Grabow

This figure shows the co-authorship network connecting the top 25 collaborators of Stephanie Grabow. A scholar is included among the top collaborators of Stephanie Grabow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephanie Grabow. Stephanie Grabow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moujalled, Diane, Adam Southon, Kerstin Brinkmann, et al.. (2022). BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells. Cell Death and Differentiation. 29(7). 1335–1348. 28 indexed citations

Ke, Francine, Graeme I. Lancaster, Stephanie Grabow, Andrew Murphy, & Andreas Strasser. (2020). Combined reduction in the expression of MCL-1 and BCL-2 reduces organismal size in mice. Cell Death and Disease. 11(3). 185–185. 5 indexed citations

Kamoun, Walid S., Anne‐Sophie Dugast, James Suchy, et al.. (2019). Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models. Molecular Cancer Therapeutics. 19(1). 270–281. 15 indexed citations

Yasmin‐Karim, Sayeda, Patrick T. Bruck, Michèle Moreau, et al.. (2018). Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer. Frontiers in Immunology. 9. 2030–2030. 68 indexed citations

Grabow, Stephanie, Andrew J. Kueh, Francine Ke, et al.. (2018). Subtle Changes in the Levels of BCL-2 Proteins Cause Severe Craniofacial Abnormalities. Cell Reports. 24(12). 3285–3295.e4. 29 indexed citations

Ke, Francine, Hannah Vanyai, Angus D. Cowan, et al.. (2018). Embryogenesis and Adult Life in the Absence of Intrinsic Apoptosis Effectors BAX, BAK, and BOK. Cell. 173(5). 1217–1230.e17. 155 indexed citations

Brinkmann, Kerstin, Stephanie Grabow, Craig D. Hyland, et al.. (2017). The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice. Cell Death and Differentiation. 24(12). 2032–2043. 18 indexed citations

Delbridge, Alex R. D., Brandon J. Aubrey, Craig D. Hyland, et al.. (2017). The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XL. Cell Death and Disease. 8(7). e2914–e2914. 17 indexed citations

Grabow, Stephanie, Alex R. D. Delbridge, Brandon J. Aubrey, Cassandra J. Vandenberg, & Andreas Strasser. (2016). Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis. Cell Reports. 14(10). 2337–2347. 35 indexed citations

10.

Grabow, Stephanie, Gemma L. Kelly, Alex R. D. Delbridge, et al.. (2016). Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis. Cell Death and Disease. 7(3). e2132–e2132. 18 indexed citations

11.

Delbridge, Alex R. D., Stephanie Grabow, Andreas Strasser, & David L. Vaux. (2016). Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nature reviews. Cancer. 16(2). 99–109. 582 indexed citations breakdown →

12.

Ke, Francine, Stephanie Grabow, Gemma L. Kelly, et al.. (2015). Impact of the combined loss of BOK, BAX and BAK on the hematopoietic system is slightly more severe than compound loss of BAX and BAK. Cell Death and Disease. 6(10). e1938–e1938. 29 indexed citations

13.

Valente, Liz J., Stephanie Grabow, Cassandra J. Vandenberg, Andreas Strasser, & Ana Janic. (2015). Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. Oncogene. 35(29). 3866–3871. 30 indexed citations

14.

Kelly, Gemma L., Stephanie Grabow, Stefan Glaser, et al.. (2014). Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes & Development. 28(1). 58–70. 126 indexed citations

15.

Delbridge, Alex R. D., Stephanie Grabow, Philippe Bouillet, Jerry M. Adams, & Andreas Strasser. (2014). Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis. Oncogene. 34(14). 1872–1876. 20 indexed citations

16.

Grabow, Stephanie, Alex R. D. Delbridge, Liz J. Valente, & Andreas Strasser. (2014). MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood. 124(26). 3939–3946. 37 indexed citations

17.

Grabow, Stephanie, et al.. (2012). Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice. Cell Death and Differentiation. 20(1). 57–63. 14 indexed citations

18.

Grabow, Stephanie, Paul Waring, Lina Happo, et al.. (2011). Pharmacological blockade of Bcl-2, Bcl-xL and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice. Cell Death and Differentiation. 19(4). 623–632. 15 indexed citations

19.

Jost, Philipp J., Stephanie Grabow, Daniel H.D. Gray, et al.. (2009). XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 460(7258). 1035–1039. 352 indexed citations

20.

Tai, Lin, Lily Lee, Elizabeth Kruse, et al.. (2009). Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature. 461(7264). 659–663. 300 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact